Mirae Asset Global Investments Co., Ltd. Viking Therapeutics, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	SELL	$17.4 - $94.5 $1.83 Million - $9.92 Million	-104,921 Reduced 76.11%	32,942 $2.7 Million
Q4 2023 Jan 24, 2024	BUY	$9.24 - $19.64 $2,716 - $5,774	294 Added 0.21%	137,863 $2.57 Million
Q3 2023 Oct 26, 2023	BUY	$10.92 - $16.0 $205,416 - $300,976	18,811 Added 15.84%	137,569 $1.52 Million
Q2 2023 Aug 10, 2023	BUY	$14.84 - $24.79 $1.46 Million - $2.44 Million	98,287 Added 480.13%	118,758 $1.93 Million
Q1 2023 May 04, 2023	BUY	$8.08 - $17.33 $165,405 - $354,762	20,471 New	20,471 $340,000

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.03B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.